Search

Now showing items 1-10 of 19

Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.

Mao, Z; Álvarez-González, C; Allen-Philbey, K; De Trane, S; Yildiz, O; Campion, T; Adams, A; Turner, BP; Marta, M; Gnanapavan, S;... (Elsevier/Science Direct, 2018-11-02)

BACKGROUND: Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with ...

Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine

Yildiz, O; Mao, Z; Adams, A; Dubuisson, N; Allen-Philbey, K; Giovannoni, G; Malaspina, A; Baker, D; Gnanapavan, S; Schmierer, K (2018-08)

TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE

Alvarez-Gonzalez, C; Allen-Philbey, K; Mathews, J; Turner, BP; Baker, D; Gnanapavan, S; Marta, M; Giovannoni, G; Schmiere, K (2016-12)

Severe skin reactions associated with cladribine in people with multiple sclerosis

Mateo-Casas, M; Reyes, S; O'Toole, EA; De Trane, S; Yildiz, O; Allen-Philbey, K; Mathews, J; Baker, D; Giovannoni, G; Schmierer, K (2020-08)

Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients

Allen-Philbey, K; De Trane, S; Stennett, A; Yildiz, O; Adams, A; Turner, B; Marta, M; Gnanapavan, S; Bianchi, L; Mathews, J;... (2021-06)

This is the accepted manuscript of an article published online: 1. ACTRIMS Forum 2021 – Poster Presentations. Multiple Sclerosis Journal. 2021;27(1_suppl):15-122. doi:10.1177/13524585211015908

Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS)

Lieberman, D; Mangat, H; Allen-Philbey, K; Baker, D; Barkhof, F; Chandran, S; Chapman, C; Chataway, J; Ford, H; Giovannoni, G;... (2020-12)

Meeting abstract P0196 from MSVirtual 2020 – 8th Joint ACTRIMS-ECTRIMS Meeting, September 11-13, 2020

Cladribine personalised dosing in people with MS (n > 200) - four years experience in clinical care.

De Trane, S; Mao, Z; Alvarez-Gonzalez, C; Allen-Philbey, K; Yildiz, O; Campion, T; Adams, A; Turner, BP; Marta, M; Gnanapavan, S;... (2018-10)

Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study

Smets, I; Holden, D; Bianchi, L; Ammoscato, F; Allen-Philbey, K; Baker, D; Turner, B; Marta, M; Giovannoni, G; MacDougall, A;... (2021)

CLADRIPLAS: Does cladribine Target CNS plasma cells and reduce neuro-axonal damage in people with MS?

Allen-Philbey, K; Andrews, M; Redha, I; Papachatzaki, M; Marta, M; Gnanapavan, S; Mathews, J; Turner, B; Giovannoni, G; Baker, D;... (2022)

CHARIOTMS - CLADRIBINE TO HALT DETERIORATION IN PEOPLE WITH ADVANCED MULTIPLE SCLEROSIS (PWAMS)

Schmierer, K; Baker, D; Nawaz, T; Allen-Philbey, K; Barkhof, F; Chataway, J; Hooper, R; Mihaylova, B; Hobart, J; Pavitt, S (2022)